Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the r...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases Vol. 27; no. 1; pp. 332 - 334
Main Authors: Haley, Connie A, Macias, Patricia, Jasuja, Supriya, Jones, Betsy A, Rowlinson, Marie-Claire, Jaimon, Roshni, Onderko, Pennelyn, Darnall, Elaine, Gomez, Maria E, Peloquin, Charles, Ashkin, David, Goswami, Neela D
Format: Journal Article
Language:English
Published: United States U.S. National Center for Infectious Diseases 01-01-2021
Centers for Disease Control and Prevention
Subjects:
antimicrobial resistance
bedaquiline
Biopsy
Care and treatment
Chemotherapy
Diagnosis
Disease control
Dosage and administration
Drug dosages
drug monitoring
Drug resistance
Extensively drug-resistant tuberculosis
FDA approval
Infectious diseases
Linezolid
Medical laboratories
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Patient outcomes
Patients
Pharmacy
pretomanid
Protein synthesis
Public health
Research Letter
Tuberculosis
tuberculosis and other mycobacteria
United States
Florida
United States > US
Illinois
linezolid
bacteria
United States
antimicrobial resistance
BPaL
Nix-TB
drug monitoring
tuberculosis and other mycobacteria
pretomanid
bedaquiline
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2701.203766